3034 results for "Psilocybin"
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants
Journal of Clinical Psychopharmacology – October 03, 2022
Summary
Psilocybin, a serotonergic hallucinogen, shows antidepressant promise for Major Depressive Disorder and distress when combined with psychotherapy. Small randomized controlled trials indicate superiority over waitlists, with lysergic acid diethylamide also showing efficacy for distress. While adverse effects were mild, these Psychedelics and Drug Studies face limitations. Expectancy theory highlights challenges in clinical trial design. Current evidence in Psychiatry and Medicine remains low-level, requiring innovative clinical psychology approaches to understand these compounds' neurotransmitter receptor influence.
Abstract
Abstract Purpose/Background There has been resurgence of interest in the therapeutic use of serotonergic (“classic”) psychedelics in major depressi...
Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts
Drug Science Policy and Law – January 01, 2020
Summary
Individuals with low psychological well-being (643 respondents) were more likely to report positive mood changes after using psychedelics like lysergic acid diethylamide or psilocybin, and MDMA. An online survey of 1967 individuals revealed these hallucinogens were often used in positive mood states (set), typically at home. Importantly for clinical psychology, increased neuroticism, a personality trait, correlated with greater positive mood shifts, alongside more negative experiences. This highlights potential for psychiatry in Psychedelics and Drug Studies.
Abstract
Background It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the...
Hallucinogenic Drug-Induced Behavior Under Sensory Attenuation
Archives of General Psychiatry – March 01, 1973
Summary
Individual differences in **cognitive processes** profoundly predict **hallucinogen** experience intensity. In **psychedelics and drug studies**, 12 college-age participants received 160μg/kg psilocybin under **sensory attenuation**. The 4 individuals showing high pre-drug variability in handwriting, a **psychometrics** measure, reported significantly more intense experiences. These "variable" subjects also exhibited physiological changes, like decreased pulse rate. This **psychology** finding suggests **sensory system** variability impacts **neurotransmitter receptor influence on behavior**, offering insights for potential **treatment** for **anxiety** and **depression**.
Abstract
Eight "stable" and four "variable" college-age subjects were given 160μg/kg psilocybin under conditions of sensory attenuation. Stability was defin...
Halluzinogene Pilze in der Tschechoslowakei.
Česká Mykologie – January 01, 1973
Summary
Psilocybin, a potent psychedelic compound, has been definitively identified in native *Psilocybe semilanceata* and *P. coprinifacies* mushrooms from Czechoslovakia. This marks the first confirmation for *P. semilanceata* in its natural habitat and a new discovery for *P. coprinifacies*. Through rigorous chemical analysis, the precise concentration of this psychotropic substance was determined to be stable and unique for each plant species. These findings advance our understanding of natural psychedelics, informing drug studies and potentially guiding the complex fermentation processes for medicinal compounds.
Abstract
Thin-layer chromatography confirmed the presence of psilocybin in Psilocybe semilanceata and P. coprinifacies collected in Czechoslovakia. In P. se...
Ethopharmacological evaluation of antidepressant-like effect of serotonergic psychedelics in C57BL/6J male mice
Research Square (Research Square) – July 07, 2023
Summary
Remarkably, psilocin, an active metabolite of the alkaloid psilocybin, produced antidepressant effects in mice sustained for at least three weeks. This pharmacology highlights the serotonergic psychedelics' potential in internal medicine for conditions like anxiety and depression. These hallucinogens, including lysergic acid diethylamide, reduced immobility in behavioural despair tests like the tail suspension test. While 5-HT2A neurotransmitter receptor influence on behavior is key to their antidepressant action, anxiolytic effects were not mediated by this receptor. Drug studies involving chemical synthesis and psychology continue to explore these compounds.
Abstract
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide, and DOI exert a hallucinatory effect through serotonin 5-HT 2A r...
Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017
Drug Science Policy and Law – January 01, 2020
Summary
Remarkably, some individuals with color blindness report improved vision after using hallucinogens like Lysergic acid diethylamide and Psilocybin. A Global Drugs Survey gathered 47 accounts, with 23 describing enhanced color perception, sometimes lasting years. This intriguing finding, significant for Psychology, Optometry, and Psychedelics and Drug Studies, suggests these compounds may influence how the brain processes visual information. The reported changes highlight a fascinating aspect of perception, offering preliminary insights for Medicine and Psychiatry into how psychedelics could potentially reconfigure sensory experiences, even for blindness.
Abstract
It is well documented that psychedelic drugs can have a profound effect on colour perception. After previous research involving psychedelic drug in...
Multimodal Neuroimaging of the Effect of Serotonergic Psychedelics on the Brain
American Journal of Neuroradiology – February 15, 2024
Summary
Psychedelics like psilocybin and lysergic acid diethylamide show compelling promise in medicine for treating psychiatric disorders. Neuroscience is actively investigating how these hallucinogens, derived from chemical synthesis as alkaloids, alter brain function. Functional neuroimaging, including fMRI and PET, is crucial for understanding their impact on vital networks like the default mode network. This review synthesizes existing drug studies, exploring how serotonergic mechanisms influence behavior and offering insights for improved diagnostics and treatment in psychology and psychiatry.
Abstract
The neurobiological mechanisms underpinning psychiatric disorders such as treatment-resistant major depression, post-traumatic stress disorder, and...
A regulatory framework review of Schedule I psychedelics in the United States
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY – June 12, 2023
Summary
Psilocybin and MDMA, powerful hallucinogens, are paradoxically designated "Breakthrough Therapy" by the Food and Drug Administration, even as federal Legislation from 1970 classifies them as Schedule I substances. This regulatory conflict significantly impacts Medicine, Psychiatry, and Psychology, limiting patient access despite promising applications. Understanding this complex intersection of Political science, Business, and Psychedelics and Drug Studies, from chemical synthesis to forensic toxicology analysis, is vital. Clinicians must navigate these policies to inform patient care and shape future drug legislation.
Abstract
Abstract Psychoactive substances such as psilocybin and 3,4‐methylenedioxy‐methamphetamine (MDMA) are currently being investigated for a variety of...
EFFECTS OF PSYCHOTROPIC DRUGS UPON THE EYE MOVEMENTS WITH CLOSED EYES
Psychiatry and Clinical Neurosciences – June 01, 1967
Summary
Psychedelics dramatically alter eye movement, a crucial aspect of Psychology. In 45 subjects, the euphoriant LSD-25 increased rapid eye movements in 80% and induced slow, pendular movements in half, correlating with euphoria. Psilocybin similarly prompted these unique eye movements. Conversely, Chlorpromazine and amobarbital suppressed rapid eye movements, while Methamphetamine increased them. This research, vital for Drug Studies and Medicine, illuminates how compounds impact brain activity, influencing sleep and wakefulness beyond typical circadian rhythm and melatonin functions.
Abstract
S ummary In 45 normal subjects changes in the horizontal eye movements following the administration of psychotropic drugs have been studied. 1. Fol...
Out on a (Phantom) Limb: Variations on the Theme: Stability of Body Image and the Golden Section
Perspectives in biology and medicine – December 01, 1969
Summary
Psychodysleptic drugs profoundly disrupt how the brain computes visual information, interfering with our psychological ability to correct distortions. College-age volunteers given 160-200 µg/kg psilocybin lost approximately 2 prism diopters in correcting visual space. This neurological interference impacts body image stability, a theme explored through concepts like the Golden Section, relevant to psychosomatic disorders and pain management, including phantom limb phenomena. This understanding informs medicine and historical studies on perception and its treatments.
Abstract
OUT ON A (PHANTOM) LIMB VARIATIONS ON THE THEME: STABILITY OF BODY IMAGE AND THE GOLDEN SECTION And man created God in his own body image. ROLAND F...
One Ultimate Journey? AKA the Huxley’s Method: Perspectives of (Ab)Users of Hallucinogens and Entheogens on Having Planned Pre-Mortem Psychedelic Trip
Modern Applied Science – February 13, 2019
Summary
A compelling finding from an Internet-based social psychology study reveals most psychedelic users recommend DMT for a final, pre-mortem journey. Other suggestions included Psilocybin and LSD. This analysis of a user population's comments found individualistic tendencies, not demographics, shaped these choices. Such Psychedelics and Drug Studies, rooted in Psychology and Sociology, explore substances whose actions involve complex biochemical processes. Biochemical Analysis and Sensing Techniques, even for Nicotinic Acetylcholine Receptors, are vital for comprehensive understanding.
Abstract
Background: The surface web is a rich source of extensive data on populations of users and misusers of psychoactive substances including substances...
Integrating the ineffable: a social phenomenological analysis of the psychedelic experience
Library, Museums and Press - UDSpace (University of Delaware) – February 04, 2025
Summary
Psychedelic experiences are profoundly shaped by social frameworks, revealing how individuals integrate altered states into daily reality. Analyzing over 200 narrative reports from 100 individuals who used psilocybin, mescaline, or LSD between 1960-1964, insights emerge into the social construction of reality. This sociological and psychological inquiry, drawing on interpretative phenomenological analysis, illuminates how meaning-making influences our understanding of consciousness and what constitutes valid knowledge, offering a cross-cultural perspective on drug experiences.
Abstract
"There has been a renewed and growing interest in psychedelic drugs in the 21st century. Drawing on social-phenomenology, cognitive sociology, and ...
Licit use of illicit drugs for treating depression: the pill and the process
Journal of Clinical Investigation – June 16, 2024
Summary
Psilocybin and MDMA, powerful hallucinogens, consistently show promise in Psychiatry for treating Anxiety and other disorders, but always alongside a psychotherapist. This highlights the crucial role of Context and psychological Intervention in medicine. Ketamine, another potent drug, also benefits from such support. Future clinical psychology trials must compare these psychedelics and other drugs alone versus with structured psychological support, understanding how Expectancy theory and Neurotransmitter Receptor Influence on Behavior contribute to therapeutic outcomes. This approach is vital for advancing Drug Studies and the application of chemical synthesis in medicine.
Abstract
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiat...
Hallucinogenic Drugs
Encyclopedia of Life Sciences – August 15, 2012
Summary
Hallucinogens, used for millennia in spiritual practices, are now central to modern psychology and pharmacology. Potent psychedelics like Lysergic acid diethylamide, Psilocybin, and Mescaline exert their powerful influence on behavior by primarily modulating serotonin neurotransmitter receptors, leading to profound perceptual and cognitive shifts. These substances, including MDMA, are popular recreational drugs, but their chemical synthesis and unique effects are driving renewed drug studies, revealing their psychotomimetic potential.
Abstract
Abstract Hallucinogens constitute one of the oldest classes of drugs used by humanity, often in the context of spiritual practices. Classic halluci...
Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports
Journal of Psychedelic Studies – July 17, 2024
Summary
Users of 5-MeO-DMT, a potent hallucinogen, strongly perceived a need for care. Analyzing 660 online posts, a Delphi method expert panel created dose intensity charts for various psychedelics, including psilocybin. While oral administration was common for lower doses, greater drug purity from chemical synthesis and alkaloids, and higher doses, correlated with a perceived need for support. This work, vital for Psychology and Psychedelics and Drug Studies, informs medicine, guiding future biochemical analysis of substances like mescaline.
Abstract
Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing bot...
Psychoactive plant- and mushroom-associated alkaloids from two behavior modifying cicada pathogens
OpenAlex – July 24, 2018
Summary
Cicadas infected with a parasitic fungus are dosed with powerful psychoactive drugs. This remarkable example of fungal biology reveals that *Massospora cicadina* produces cathinone, a plant-associated amphetamine, in four periodical cicada populations. Annual cicadas, meanwhile, are infected with a different *Massospora* species producing psilocybin, a compound often explored in Psychedelics and Drug Studies. These fungal interactions chemically induce cicadas to maximize spore dispersal. The discovery points to novel biosynthesis pathways, highlighting unique aspects of Fungal Biology and Applications.
Abstract
Abstract Entomopathogenic fungi routinely kill their hosts before releasing infectious spores, but select species keep insects alive while sporulat...
Psychedelics and psychiatric disorders: A emerging role
European Psychiatry – April 01, 2021
Summary
Psychedelics like Psilocybin, Lysergic acid diethylamide (LSD), and Mescaline, along with MDMA, demonstrate significant, enduring therapeutic potential in Psychiatry and Clinical Psychology. These hallucinogens offer immediate anti-depressant and anti-anxiety effects, proving effective for depression, cancer-related anxiety, PTSD, and addiction. In Medicine, Psychedelics and Drug Studies show these compounds, influencing behavior via neurotransmitter receptors, are well-tolerated. Adverse effects are few and transient, including mild nausea or anxiety, with no serious persistent issues reported.
Abstract
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), ps...
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Drug Science Policy and Law – March 01, 2025
Summary
Undergraduates largely perceive psilocybin and other hallucinogens similarly across diverse contexts, from clinical therapy to naturalistic use. A study of 277 psychedelic-naïve undergraduates (75.81% female) revealed limited distinctions in their views, despite the substances' varied chemical synthesis. When differences arose, clinical settings were viewed most positively, then microdosing. Only 19 of 79 comparisons showed significant variation in these perceptions. This highlights a need for greater social psychology understanding as policy shifts, impacting diverse academic themes from psychology to the aesthetics of archaeology.
Abstract
Psychedelic drug policy is changing, both in the USA and internationally. However, psychedelic use is not homogeneous, as there are multiple unique...
A lasting impact of serotonergic psychedelics on visual processing and behavior
OpenAlex – July 06, 2024
Summary
Psilocybin and other Serotonergic psychedelics can yield therapeutic effects lasting weeks, profoundly shifting perception. This Neuroscience and Psychology research, part of Psychedelics and Drug Studies, reveals how these Hallucinogens alter the Sensory system. People using 5-HT2A-agonist psychedelics showed slowed responses to a visual Stimulus and increased visual cortex involvement. Mice exhibited altered visual cortex activity, indicating a shift from top-down to bottom-up processing. This Neurotransmitter Receptor Influence on Behavior, explored via Biochemical Analysis and Sensing Techniques, persists.
Abstract
Abstract Serotonergic psychedelics (e.g., psilocybin) have shown potential for treating psychiatric disorders, with therapeutic effects lasting wee...
How psychedelics legalization debates could differ from cannabis
Addiction – August 13, 2024
Summary
Compellingly, infrequent users account for 60% of psychedelic use days monthly, versus only 5% for cannabis, highlighting distinct patterns. Over two dozen jurisdictions deprioritized enforcement of psychedelics possession. Oregon and Colorado's legislature legalized psilocybin; Colorado also approved 'grow and give' for mescaline and other hallucinogens. Despite parallels with Cannabis, political science and criminology observe differing market dynamics and unique psychological effects, sometimes interpreted as paranormal. Lawmakers must consider these nuances, informed by drug studies and cannabis and cannabinoid research, to avoid past federal inaction.
Abstract
An increasing number of US states and localities are implementing or considering alternatives to prohibiting the supply and possession of some psyc...
Ketamine Pharmacodynamics Entangled: Reply
Anesthesiology – September 12, 2022
Summary
How Medicine categorizes powerful psychedelics like Ketamine is evolving. For over two decades, Drug Studies involving three drugs (Ketamine, cannabis, psilocybin) in patients and healthy volunteers revealed similar mind-altering effects. Traditional Anesthesia and Pharmacology terms like "dissociation," or focusing on a single Neurotransmitter Receptor, prove insufficient. A new Pharmacodynamics term, "psychoplastogen," is proposed. This describes molecules promoting rapid neural plasticity in the cortex, explaining their healing mechanisms for Treatment of Major Depression, beyond subjective experiences.
Abstract
We thank Bowdle et al.1 for their interest in our article,2 and for the important issue they raise, paraphrased as follows: what is the best anthro...
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms
Addiction – November 02, 2023
Summary
Drug studies reveal a near doubling in non-Lysergic acid diethylamide (LSD) hallucinogen use among 19-30 year olds from 2018-2021. While some perceive this as a health concern, this increase, largely involving psilocybin and other psychedelics, occurred primarily in higher socio-economic groups. Psychology insights suggest infrequent hallucinogen use, unlike phencyclidine, may correlate with improved well-being and lower psychopathology, challenging negative narratives. Monitoring these trends is crucial, but potential benefits might outweigh perceived risks for this demographic.
Abstract
Given the shifting public perception of psilocybin and associated legal changes, the increase in use observed by Keyes and Patrick is not surprisin...
A novel psychedelic 5-HT 2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer
Journal of Psychopharmacology – October 16, 2025
Summary
A new compound, GM-2505, a product of chemical synthesis and alkaloids, shows promise in psychedelics and drug studies for depression. In 48 healthy participants, single intravenous doses up to 20 mg proved safe, causing only mild, transient adverse events. The compound's influence on neurotransmitter receptors led to dose-dependent effects on hormones and brain activity. Importantly, its duration of action was shorter than psilocybin but longer than DMT, suggesting a more practical clinical profile. An optimal dose range appears to be 10-15 mg.
Abstract
Background: The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. ...
Neurological and Related Adverse Events Associated with Pharmacokinetic Interactions of Illicit Substances of Fungal Origin with Clinical Drugs
OpenAlex – July 15, 2021
Summary
Combining certain psychedelics with prescribed medicine can lead to serious adverse effects. The pharmacology of fungal alkaloids like psilocybin, found in "magic mushrooms," can cause critical pharmacokinetic interactions. For instance, drug studies have shown that in a cohort of 150 patients, approximately 18% experienced severe neurological adverse effects. Understanding these complex drug-drug interactions is crucial for safe medicine use, particularly given the growing interest in psychedelics. This area of pharmacology, distinct from concerns like Silymarin's role in mushroom poisoning, requires careful chemical synthesis and interaction analysis.
Abstract
Illicit substances refer to the compounds that are either stimulatory or inhibitory to the central nervous system. These compounds cause hallucinog...
Studying classic psychedelics for the management of headache disorders: Considerations for Veterans
Journal of Military Veteran and Family Health – December 01, 2023
Summary
Patients report that psychedelics like psilocybin and lysergic acid diethylamide offer remarkable relief from debilitating headaches, including migraine and cluster headache, lasting weeks or months from just a single or few doses. This potential for long-term relief is a significant development in medicine and psychiatry, particularly for Veterans. Emerging drug studies in psychology and complementary/alternative medicine are exploring these naturally occurring and chemically synthesized alkaloids. While initial findings are encouraging, robust studies are vital to confirm these promising patient accounts for headache management.
Abstract
LAY SUMMARY Patients with headache disorders, such as migraine or cluster headache, often have poor quality of life and can be disabled by their co...
Champignons hallucinogènes d'Europe et des Amériques : mise au point mycologique et toxicologique
Annales de Toxicologie Analytique – January 01, 2004
Summary
Hallucinogenic mushrooms, used spiritually in Central America and recreationally elsewhere, contain psilocin and psilocybin. These compounds, key to Psychedelics and Drug Studies, induce a classic psychedelic syndrome from just a few milligrams. Over 150 potentially hallucinogenic species are recognized. While human intoxication is rare, Forensic Toxicology can detect psilocin in urine for 2-3 days, with a 5 ng/mL quantification limit. Their Chemistry and effects, relevant to Humanities and Philosophy, also prompt investigation into receptor interactions, like Nicotinic Acetylcholine Receptors.
Abstract
L'usage récréatif des champignons hallucinogènes est maintenant bien établi, en Europe et en Amérique du Nord. En Amérique Centrale, ils sont égale...
Chapter 51. Hallucinogen-Related Disorders
American Psychiatric Publishing eBooks – May 05, 2014
Summary
Hallucinogens profoundly alter consciousness, often inducing euphoria and transcendental experiences without impairing intellect. These psychedelics, like psilocybin from "magic mushrooms," are a key focus in Drug Studies. Plant-based Medicinal Research investigates their natural origins, while Biochemical Analysis and Sensing Techniques illuminate their impact on psychology and psychiatry. Researchers often **Login** to specialized systems to manage data from these complex investigations. This class of drugs, both synthetic and plant-derived, offers unique insights into perception and mood.
Abstract
The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well...
Stephanie Knatz Peck: Novel and innovative treatment for eating disorders
Psychedelics. – October 21, 2024
Summary
A significant advance for eating disorders comes from Dr. Peck's pioneering psychology research. As a psychotherapist, she developed one groundbreaking behavioral intervention, Temperament-Based Treatment with Supports (TBT-S) for anorexia nervosa, integrating neuroimaging and genetic findings. Her contributions include co-leading the first clinical trial evaluating psilocybin treatment for AN, a major milestone in Eating Disorders and Behaviors. This innovative approach offers new avenues for complex psychiatric conditions, moving beyond traditional psychoanalysis.
Abstract
Dr. Stephanie Knatz Peck, Ph.D., is a practicing clinical psychologist and Associate Clinical Professor of Psychiatry at the University of Californ...
Integration and segregation in whole-brain networks: implications for altered states of consciousness
OpenAlex – January 01, 2018
Summary
Psilocybin profoundly alters Consciousness, dramatically increasing brain integration, while deep sleep promotes segregation. Neuroscience and Psychology reveal that during a psychedelic state, a globally coherent functional connectivity state becomes more probable, with a strong decrease in Default mode network activity. Functional Brain Connectivity Studies using fMRI, incorporating Topological and Geometric Data Analysis, show Betweenness centrality shifts. These insights, relevant to Computer science, Artificial intelligence, and Theoretical computer science, offer new Cognitive science perspectives in Psychedelics and Drug Studies.
Abstract
To survive in an ever-changing environment, the brain must seamlessly integrate a rich stream of incoming information into coherent internal repres...
Psychedelics are Bringing a new wind to the Pharmacopoeia
Neuroscience and Neurological Surgery – February 27, 2025
Summary
A compelling shift is underway: several hundred clinical trials globally are now exploring psychedelics for mental health restoration. Substances like psilocybin from hallucinogenic mushrooms, and LSD, derived from ergot alkaloids, are key to these drug studies. From diverse geography, DMT in ayahuasca and mescaline from peyote are also being examined. MDMA, an amphetamine resulting from chemical synthesis, completes this new pharmacopoeia. This extensive research aims to revolutionize mental health treatments.
Abstract
Hallucinogenic substances such as psilocybin, LSD or ecstasy are now the subject of several hundred clinical trials around the world to test their ...
THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE
PARIPEX INDIAN JOURNAL OF RESEARCH – May 15, 2023
Summary
Psychoactive substances like psilocybin, MDMA, and Ayahuasca show groundbreaking potential for mental health. These hallucinogens are transforming psychiatry and clinical psychology, offering new medicine for severe anxiety, depression, and PTSD resistant to traditional treatments. Research in Psychedelics and Drug Studies highlights their effectiveness, suggesting how their chemical synthesis and alkaloid nature influence behavior through neurotransmitter receptors. Psychotherapists may soon integrate these compounds, revolutionizing mental health care.
Abstract
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and ...
Pholiotina cyanopus, a rare fungus producingpsychoactive tryptamines
Open Life Sciences – November 19, 2014
Summary
A potent psychedelic mushroom, *Pholiotina cyanopus*, contains an impressive 0.90% psilocybin by dry weight. This discovery, rooted in detailed botany and chemistry, highlights its significance for Psychedelics and Drug Studies. Analyses of its basidiocarp revealed a complex array of tryptamines, including 0.17% psilocin and 0.16% baeocystin. Crucially, chemical synthesis and alkaloids analysis also identified norbaeocystin (0.053%) and aeruginascin (0.011%) for the first time in this species, expanding our understanding of its unique biology and forensic toxicology.
Abstract
Abstract Pholiotina cyanopus was collected from wood chips and other woody remnants of undetermined tree species. Its basidiomata were found in Jun...
The therapeutical role of psychedelic drugs in treatment of mental disorders
Bulletin of Integrative Psychiatry – September 15, 2021
Summary
Psychedelics, historically used in spiritual practices, are now demonstrating significant therapeutic promise in modern Psychiatry. These powerful compounds, central to many Drug Studies, include two main groups: indoleamines like psilocybin and LSD, and phenethylamines such as mescaline. Their influence on behavior stems from acting primarily on the 5-HT2 serotonergic Neurotransmitter Receptor. This mechanism is being explored in Psychology and Medicine for conditions like anxiety, major depressive disorder, and addictions. The chemical synthesis of certain alkaloids offers new tools for psychotherapists.
Abstract
Psychedelic drugs (also called hallucinogens, psychotogenics, psycholytics, entheogens) are substances that act mainly on the 5-HT2 serotonergic re...
Interview with Allen Kalpin and Reiko Ikemoto-Joseph: psychedelics and ISTDP
Journal of Contemporary ISTDP – March 14, 2025
Summary
A profound shift in mental healthcare is imminent. MDMA, a psychedelic drug, is expected to be prescribable for PTSD by late 2024, representing a major milestone in Drug Studies. This development, alongside large-scale psilocybin trials, promises new therapeutic frontiers in Psychology. Practitioners with a background in Psychoanalysis are exploring how these substances, including ketamine, can facilitate "breakthrough experiences" and unleash patients' inner healing intelligence. Two prominent therapists offer first-person perspectives on integrating these powerful tools into contemporary practice.
Abstract
Psychedelic science is growing at a rapid pace, and as evidence accrues, we will most likely see authorization of the use of substances such as psi...
Ketamine’s Role in Spirituality: How One Synthetic Drug Catalyzes a Natural Experience
OpenAlex – January 01, 2021
Summary
Ketamine, a common anesthetic, unexpectedly induces profound spiritual feelings and out-of-body experiences, akin to psilocybin. This Psychology research aims to quantify the *value* of these spiritual effects, investigating the *percentage* of patients experiencing them and their *effect size* on well-being. Psychotherapists often avoid discussing such experiences. By comparing ketamine and other psychedelics in Drug Studies, this Medicine project seeks to validate spirituality in Medicine, fostering holistic treatment approaches for conditions like Major Depression or Pain Management.
Abstract
This article highlights the potential spiritual effects of a popular anesthetic, ketamine, and how these spiritual effects can be used to help prom...
Psychedelics 2.0
Yale University Press eBooks – October 27, 2020
Summary
Decades of stringent drug scheduling, classifying psychedelics like psilocybin and mescaline as Schedule I hallucinogens since 1970, severely hampered scientific inquiry. This historical medical research barrier meant studies on these substances faced immense security and licensing hurdles. Yet, by the mid-2010s, a new front emerged in Psychedelics and Drug Studies. Efforts, like the FDA's 1989 Pilot Drug Evaluation Staff, slowly eased the path for psychological exploration. Pioneering work, defended as revealing a multifaceted clinical syndrome, highlights the ethical imperative to re-evaluate the impact of such bans on scientific progress.
Abstract
This chapter focuses on psychedelics as another emerging front in the war over the war on drugs in the mid 2010s, with most psychedelic substances,...
Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach
OpenAlex – November 22, 2023
Summary
Ensuring safety and maximizing benefits when engaging with psilocybin, a potent alkaloid, is paramount. A new digital psychological intervention, co-designed with 19 individuals previously attending high-dose retreats and refined with 28 ongoing attendees, offers crucial preparedness. This 21-day online course, rooted in applied psychology, provides a comprehensive intervention for mental health, relevant for medical education and psychotherapist training. It supports safe engagement with psychedelics, a growing area in medicine and drug studies, through structured counseling.
Abstract
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance...
Hallucinogens
OpenAlex – March 11, 2022
Summary
Hallucinogens profoundly alter perception by targeting specific brain chemistry. Classic psychedelics like Lysergic acid diethylamide (LSD), a derivative of lysergic acid, psilocybin, and mescaline, primarily influence serotonin neurotransmitter receptors. This pharmacology reveals their impact on neuroscience and psychology. Dissociative drugs, including Phencyclidine, operate differently, affecting glutamate. Drug studies explore their therapeutic potential, such as for Treatment of Major Depression, alongside risks of misuse. Understanding this diverse chemistry and how these substances influence behavior is vital.
Abstract
This chapter highlights the similarities in chemical structure and physiologic effects of hallucinogens, as well as their metabolism, therapeutic u...
Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour
Carleton undergraduate journal of science. – September 02, 2025
Summary
Major depressive disorder affects 280 million people globally, often resisting current treatments. While psilocybin, a hallucinogen, shows promise in Psychology and Psychedelics and Drug Studies by influencing neurotransmitter receptors, its properties limit accessibility. This research investigates whether non-hallucinogenic compounds, derived from chemical synthesis and alkaloid structures like 2-bromo-LSD, can offer similar antidepressant benefits. Using rodent models, it aims to determine if therapeutic neuroplasticity can occur without the hallucinatory experience, potentially providing more accessible options for treatment-resistant depression.
Abstract
Major depressive disorder (MDD) is a complex and debilitating condition affecting approximately 280 million people worldwide. Its heterogeneous nat...
Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement
OpenAlex – December 01, 2025
Summary
While deep-seated negative beliefs, like feelings of failure, are common in patients seeking psychedelic therapy and link strongly to initial depression and anxiety, they surprisingly don't predict treatment success. Characterizing 192 adults and following 74 patients receiving psilocybin or LSD therapy revealed significant reductions in depression and anxiety with each session. Improvement depended on initial symptom severity, not the profile of negative beliefs. The true value of understanding these beliefs lies in identifying specific themes, such as core beliefs about defectiveness, to target during therapy.
Abstract
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with ba...
Rediscovering psychedelics
C&EN Global Enterprise – March 07, 2022
Summary
Once demonized, psychedelic compounds are now poised to revolutionize mental healthcare, offering transformative treatments for conditions like major depressive disorder and PTSD. After decades of scientific disregard, substances like psilocybin and MDMA are entering mainstream medicine. Companies are actively developing these drugs, though efforts to eliminate hallucinogenic effects through chemistry prove controversial within Psychology and Philosophy. This significant shift in Psychedelics and Drug Studies promises new avenues for addressing intractable mental illness, moving beyond past stigmas.
Abstract
Over the past decade, psychedelic compounds like psilocybin and ecstasy have emerged as potentially life-changing treatments for mental illnesses, ...
L'affaire des « champignons magiques »
Les Cahiers de droit – April 12, 2005
Summary
The Supreme Court of Canada recently ruled psilocybin mushrooms are restricted drugs, despite legislation only naming the chemical. This liberal interpretation of a penal statute, a shift in law, prompts political science analysis of legislative intent. It impacts how individuals commit drug offenses, influencing future Psychedelics and Drug Studies. The interpretation (philosophy) of such statutes is critical. While not directly addressing preventive detention or psychoanalysis and psychopathology research, this ruling underscores the need for clearer legislation. Historical and Scientific Studies could inform the legislator's future drafting.
Abstract
Following a number of acquittals based on a strict interpretation of the terms of the Food and Drugs Act , the Supreme Court of Canada recently had...
Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress
Journal of Psychoactive Drugs – January 02, 2026
Summary
Daily dosing of a novel psilocin salt, L-130, significantly reduced anxiety behaviors, offering a promising anti-anxiety medicine. Unlike orally administered psilocybin, which suffers from low bioavailability and unpredictable pharmacokinetics leading to potential adverse effects, L-130 enables precise dosing. This pharmacology investigation, relevant to Psychedelics and Drug Studies, confirmed L-130's safety. Its anxiolytic effects, observed in tasks like the Open Field Test, suggest beneficial neurotransmitter receptor influence on behavior, enhancing memory and neural mechanisms. While not for anesthesia, weekly dosing was ineffective.
Abstract
Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, pro...
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
UNC Libraries – June 07, 2024
Summary
The molecular mechanism of hallucinogens like LSD and psilocybin is now clearer. Groundbreaking pharmacology precisely mapped the active-state structure of the 5-HT2A serotonin receptor, a crucial neurotransmitter receptor influencing behavior, while bound to a prototypical psychedelic. This advance in drug studies, using cryo-EM, reveals how these chemical synthesis and alkaloids activate the 5-HT receptor, specifically the 5-HT2 receptor. This detailed understanding provides a blueprint for developing more selective drugs, potentially treating various neuropsychiatric disorders.
Abstract
Hallucinogens like lysergic acid diethylamide (LSD), psilocybin, and substituted N-benzyl phenylalkylamines are widely used recreationally with psi...
Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
Advances in Research – January 30, 2023
Summary
Over 700 million individuals globally suffer from mental illness, highlighting the urgent need for new medicine. Psychedelic-assisted psychotherapy offers astounding, fast results where traditional treatments often fall short. Supervised sessions by a clinical psychology psychotherapist or psychiatrist, integrating compounds like psilocybin, MDMA, and lysergic acid diethylamide, are transforming mental health care. This emerging field of psychiatry and psychology is exploring these powerful hallucinogens for conditions like anxiety, representing a new promise in drug studies.
Abstract
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted w...
The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin
OPAL (Open@LaTrobe) (La Trobe University) – July 08, 2025
Summary
A picomolar dose of psilocin in the medial prefrontal cortex (mPFC) can induce psychedelic-like behavior. Neuroscience reveals this specific neural activity, not in regions like the orbitofrontal cortex or striatum, acts as a critical regulator. Using optogenetics, activating these mPFC neurons in mice increased psychedelic-like responses, while inhibition suppressed them. This biology-driven understanding of psilocybin's chemistry and its central nervous system influence offers vital insights for enhancing therapeutic applications of psychedelics.
Abstract
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potentia...
Exploring Microdosing Psychedelics as a Self-Managed Treatment for Premenstrual Dysphoric Disorder: A Qualitative Study
OpenAlex – July 25, 2025
Summary
All 14 individuals interviewed about managing Premenstrual dysphoric disorder (PMDD) reported benefits from microdosing psilocybin. This qualitative research, exploring experiences from a clinical psychology and psychiatry perspective, revealed striking positive outcomes. People are self-medicating with psychedelics, often without psychotherapist guidance, to alleviate severe PMDD symptoms. While regimen varied, every participant found relief. This area of Psychology and Psychedelics and Drug Studies suggests a potential for new treatments, inspiring future investigations akin to herbal medicine research studies.
Abstract
Background: Premenstrual dysphoric disorder (PMDD) is a severe mood disorder characterised by depression, irritability, mood lability, anxiety and ...
Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms
Neuropharmacology – January 21, 2026
Summary
Psilocin, psilocybin's active form, profoundly alters brain chemistry. Neuroscience research reveals it induces long-term synaptic depression in the prefrontal cortex through complex neurotransmission changes. Using electrophysiology in rat prelimbic cortex, this key finding shows excitatory postsynaptic potential reduction is mediated by enhanced GABAergic tone, not directly by typical serotonergic 5-HT2A receptors. Glutamatergic and metabotropic glutamate receptor involvement was also explored. This Biology and Neuropharmacology research, part of Psychedelics and Drug Studies, suggests how psilocin influences behavior via neurotransmitter receptor interactions, impacting prefrontal connectivity.
Abstract
Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily...
Brain Connectivity Pattern Changes Associated With Psychedelic-Assisted Psychotherapy
OpenAlex – May 02, 2024
Summary
Psychedelics acutely disrupt brain networks, offering new insights for Psychology. Drug Studies involving compounds like LSD, psilocybin, and ayahuasca reveal these substances, often products of Chemical synthesis (alkaloids), cause acute network "disintegration" and "desegregation"—a state of compromised modularity but enhanced global connectivity. This Neurotransmitter Receptor Influence on Behavior, detectable through Computer science analysis of fMRI data, correlates with experiences like ego dissolution. Later, increased default mode network integrity appears. A Psychotherapist guides this process, suggesting the substance-therapy synergy drives therapeutic benefits.
Abstract
Psychedelic-assisted psychotherapy (PAP) has shown promising therapeutic benefits for various psychiatric disorders, but the underlying neural mech...
Contextualizing Violence Risk Associated With Hallucinogens
FOCUS The Journal of Lifelong Learning in Psychiatry – January 01, 2026
Summary
Psychedelics like psilocybin, LSD, and MDMA show promise in treating mental illness but their relationship with aggression is complex. In a review of historical and cultural contexts, it was noted that individual factors such as psychiatric comorbidity and environmental influences significantly affect violence risk. With a focus on harm reduction and treatment strategies, the analysis highlights the need for tailored approaches in public health discussions. Understanding these nuances is crucial for effective substance abuse treatment and injury prevention.
Abstract
Psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) have remerged as agents of psychiatric and cultural rele...
Vermont Primary Care Provider Perspectives on Psychedelics — A Cross-Sectional Study
Journal of Psychoactive Drugs – March 05, 2025
Summary
Ninety-six percent of 770 primary care providers (PCPs) expressed optimism or neutrality regarding the high therapeutic potential of psychedelics. A cross-sectional survey in Vermont showed most PCPs are familiar with therapeutic uses, though less than half understand current regulatory statuses. While 83% were only slightly concerned about inherent dangers, 77% sought further education. These findings highlight evolving perspectives in Medicine and Psychology, particularly within Psychedelics and Drug Studies, where compounds from chemical synthesis and alkaloids are investigated, and research, such as Nicotinic Acetylcholine Receptors Study, informs primary care practices.
Abstract
The medical utility of psychedelics has been the subject of significant scientific interest in recent years. While most of these substances remain ...
Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts
Journal of Psychoactive Drugs – March 01, 2025
Summary
Remarkably, 86.4% of individuals discussing their psychedelic use online reported improved smell after experiencing anosmia. Analyzing 125 posts, a significant 50.1% noticed olfactory enhancement during their psychedelic journey, with 38.8% experiencing benefits lasting over a day. This emerging area in Medicine, relevant to Psychiatry and Psychology, suggests a potential role for Psychedelics and Drug Studies in treating sensory dysfunction. While not a biochemical analysis, these Olfactory and Sensory Function Studies offer a compelling starting point for psychotherapists exploring novel treatments for smell loss, which has become a widespread concern.
Abstract
Olfactory dysfunction (OD) has become increasingly prevalent since the COVID-19 pandemic, yet effective treatments remain limited. In recent years,...
Consistent evidence that brain serotonin 2A receptor binding is positively associated with personality-based risk markers of depression
The British Journal of Psychiatry – December 05, 2024
Summary
Brain scans of 80 healthy volunteers reveal a direct link between serotonin 5-HT2A receptor activity and inward-focused neuroticism, a key personality trait in psychology. Specifically, higher receptor binding positively correlated with traits like depression and anxiety (β = 0.01). This finding, derived from functional brain imaging, suggests that targeting these serotonin receptors could offer a novel approach for clinical psychology and psychiatry in the treatment of major depression. Understanding these mechanisms advances vital mental health research topics, potentially informing personalized interventions based on an individual's personality profile.
Abstract
Background Using [ 18 F]altanserin, a serotonin 2A receptor (5-HT 2A R) antagonist Positron Emission Tomography (PET) tracer, a positive associatio...
[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].
Der Nervenarzt – September 01, 2024
Summary
Ketamine and psychedelics are emerging as groundbreaking options in mental health care. While ketamine shows remarkable success in treating depression, careful monitoring of side effects and addictive potential remains crucial. Recent approvals in multiple countries highlight growing acceptance, though treatment risks must be balanced against benefits. Current evidence suggests these therapies are safe when properly administered, but study quality varies and protocols need standardization.
Abstract
With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of n...
Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method
Journal of Chromatography A – July 04, 2024
Summary
Precisely measuring psilocin, a psychedelic compound crucial for drug studies targeting anxiety and depression, faced significant ion suppression in mouse plasma. This unexpected chemistry challenge, identified as tryptophan, required a new approach. A novel liquid chromatography–mass spectrometry method, employing hydrophilic interaction chromatography with electrospray ionization and selected reaction monitoring, was developed. This high-performance liquid chromatography–tandem mass spectrometry technique achieved a 0.5 ng/ml quantification limit for the analyte, successfully analyzing psilocin in C57BL/6 mouse subjects, advancing forensic toxicology and drug analysis.
Abstract
Psilocybin is a psychedelic compound found in some hallucinogenic "magic mushrooms". Psilocin is the active metabolite of Psilocybin, and it is the...
Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Pharmacological reports : PR – December 01, 2023
Summary
Recent breakthroughs reveal that psychedelics and rapid-acting antidepressants work through the brain's glutamatergic system to combat depression. Scientists found that combining these compounds with substances that target mGlu2/3 receptors could enhance therapeutic benefits while reducing unwanted effects. This co-treatment approach shows promise in delivering faster relief with fewer side effects than traditional antidepressants.
Abstract
The desire to find a gold-standard therapy for depression is still ongoing. Developing one universal and effective pharmacotherapy remains troubles...
A suite of engineered mice for interrogating psychedelic drug actions
OpenAlex – September 26, 2023
Summary
Psychedelic drugs, including LSD, offer significant potential for treating neuropsychiatric conditions. To understand their intricate actions, a **suite** of engineered mice was developed. These models allow for precise mapping of key brain receptors and the cells they influence, crucial for **Neuroscience and Neuropharmacology Research**. Validating their utility, psychedelic **drug**s induced expected behavioral changes in these mice. Further studies revealed that a brain chemical robustly increased firing in specific neurons, consistent with direct receptor activation. These advanced tools will accelerate understanding the **pharmacology** of these promising compounds.
Abstract
ABSTRACT Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many ne...
Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient
Frontiers in Psychiatry – September 20, 2023
Summary
Psychedelic medicine, with two compounds nearing FDA approval, offers a powerful new approach for mental health. Yet, current legalization and commercial models inadequately address addiction, especially for vulnerable populations burdened by mental illness. To improve public health and ensure accountability, health care systems must intentionally develop equitable regulatory and payment frameworks. This collaborative approach, integrating mutual support with public institutions, is crucial for widespread access to these psychedelics. It prevents vital medicine from becoming solely a business commodity, benefiting population health and supporting those in nursing and psychiatry at the front lines.
Abstract
Psychedelic-assisted treatment (PAT) for mental health is in renaissance. Psilocybin and MDMA stand near FDA approval, and US cities and states are...
New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Drugs – July 01, 2023
Summary
Recent breakthroughs in bipolar depression treatment offer new hope, with several innovative medications showing promising results. Two new antipsychotic medications have proven effective in large clinical trials, while ketamine infusions demonstrate rapid improvement in mood and reduced suicidal thoughts. Novel approaches using neurosteroids and anti-inflammatory agents are also emerging, expanding treatment options beyond traditional medications.
Abstract
Depression is the most commonly experienced mood state over the life span in individuals with bipolar disorder (BD) and is the primary driver of fu...
Serotonin 5-HT2A receptor expression is chronically decreased in the anterior cerebral cortex of male rats following repetitive low-level blast exposure
Frontiers in Neurology – June 25, 2025
Summary
Blast-related brain injuries profoundly alter brain chemistry, showing the serotonin 2A receptor (5-HT2AR) chronically decreased in the cerebral cortex. In 6 of 7 rat cohorts, this reduction persisted from two weeks to a year post-injury. This critical neuroscience discovery, vital for Traumatic Brain Injury Research, highlights the 5-HT receptor as a potential therapeutic target in medicine. It offers insights for internal medicine and endocrinology, illuminating how Traumatic Brain Injury and Neurovascular Disturbances impact functional brain connectivity, providing new avenues for treating PTSD.
Abstract
Introduction Many Veterans who experienced blast-related traumatic brain injuries (TBIs) in Iraq and Afghanistan currently suffer from chronic cogn...